Published 4 issues per year
ISSN Print: 0893-9675
ISSN Online: 2162-6448
Indexed in
Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma
ABSTRACT
Over the past couple of decades, with discovery of novel targeted therapies, and expansion of our understanding of the molecular biology of rectal cancer, there has been an emergence of a wide variety of therapeutic options designed to facilitate a personalized approach for the treatment of this malignancy. A plethora of new prognostic and predictive single genes and proteins are being discovered that may reflect susceptibility and/or resistance to therapy. Pathologic complete response rates occur in 10-16% of patients and have been shown to correlate with both disease-free and overall survival. However, the response to neoadjuvant therapy remains variable and unpredictable. In this review, some of these novel markers are discussed for their potential use as pharmacogenetic predictors for specific therapy, drug toxicity, and disease outcome.
-
Molinari Chiara, Matteucci Federica, Caroli Paola, Passardi Alessandro, Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer, Clinical Colorectal Cancer, 14, 4, 2015. Crossref
-
Brown Gordon T., Cash Beatriz Gimenez, Blihoghe Daniela, Johansson Petronella, Alnabulsi Ayham, Murray Graeme I., Kyprianou Natasha, The Expression and Prognostic Significance of Retinoic Acid Metabolising Enzymes in Colorectal Cancer, PLoS ONE, 9, 3, 2014. Crossref